Blood‐based biomarker for identifying post‐mortem confirmed Cerebral Amyloid Angiopathy

Abstract

Background: Cerebral amyloid angiopathy (CAA) is a cerebrovascular disorder characterized by the deposition of amyloid‐β (Aβ) in the walls of leptomeningeal and cortical blood vessels leading to increased risk of microbleeds, intracerebral hemorrhages, and progressive cognitive decline.

The paper